AusperBio Reports Significant Progress in Advancing AHB-137 Clinical Development
Friday, July 05, 2024
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a biotechnology firm specializing in oligonucleotide therapies, have made significant strides in developing AHB-137, their lead candidate for treating chronic hepatitis B (CHB) infection.
Key milestones include:
- Enrollment of 193 participants, including 101 CHB patients, providing extensive safety and efficacy data for AHB-137.
- Completion of Phase 1b studies in China and globally, with findings presented at EASL 2024.
- Successful conclusion of patient enrollment for the Phase 2a study in China.
- Completion of large-scale manufacturing of the AHB-137 drug product.
AusperBio, highlighted the program's progress and recognition at EASL 2024 for AHB-137's safety and efficacy. Dr. Chris Yang, Co-founder and CSO, emphasized the rapid Phase 2a enrollment and plans for further data analysis later this year.
AHB-137, an innovative unconjugated antisense oligonucleotide developed using AusperBio's Med-Oligo™ ASO technology platform, targets all HBV mRNA with the potential to serve as a foundational treatment for CHB, aiming for a functional cure. Chronic hepatitis B affects nearly 290 million people globally, underscoring the urgent need for effective therapies to prevent severe liver diseases.
Source: prnewswire.com
